Abstract
Sixty-two patients with Hodgkin's disease have been followed for one year from the start of treatment. Immunological assessments were repeated after intensive treatment, in patients relapsing and in those in remission at one year. In patients achieving remission, overall cellular immunity, after deteriorating with therapy, particularly cytotoxic chemotherapy, returned to pre-treatment levels in remission when there was little evidence of cellular immune disturbance. Serum IgG and IgM levels fell with intensive chemotherapy in splenectomized patients. IgA and IgM levels were lower (irrespective of splenectomy or therapy status) in remission than at presentation or after treatment. Relapse or non-response was usually associated with deteriorating cellular immunity. Herpes zoster/varicella and candida infections (seen in 6 patients) were preceded by, or associated with, deterioration of cellular immunity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Hancock, B., Bruce, L., Dunsmore, I. et al. Follow-up studies on the immune status of patients with Hodgkin's disease after splenectomy and treatment, in relapse and remission. Br J Cancer 36, 347–354 (1977). https://doi.org/10.1038/bjc.1977.199
Issue Date:
DOI: https://doi.org/10.1038/bjc.1977.199
This article is cited by
-
Systemic varicella-zoster virus infection in two critically ill patients in an intensive care unit
Virology Journal (2013)
-
The overwhelming postsplenectomy sepsis problem
World Journal of Surgery (1980)